Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database

Table 1 Patient baseline characteristics

	GEM-E (n = 1,331)	GEM (n = 2,936)	p-value^a
	No. (%)	No. (%)	p-value^a
Sex
Male	861 (64.69)	1,743 (59.37)	0.0010
Female	470 (35.31)	1,193 (40.63)
Age, years
Mean ± SD	61.89 ± 9.76	63.38 ± 10.40	<0.0001
Median	63	65
Range	28–88	18–92
18–29	2 (0.15)	6 (0.20)	<0.0001
30–39	16 (1.20)	42 (1.43)
40–49	128 (9.62)	268 (9.13)
50–59	387 (29.08)	683 (23.26)
60–69	486 (36.51)	1,010 (34.4)
70–79	295 (22.16)	825 (28.1)
Above 80	17 (1.28)	102 (3.47)
Charlson Comorbidity Index (CCI)
Mean ± SD	8.88 ± 3.39	9.14 ± 3.40	0.0206
Median	10	10
Range	2–18	2–19
Comorbidity score
≤ 3	102 (7.66)	222 (7.56)	0.2024
4–6	246 (18.48)	476 (16.21)
7–9	302 (22.69)	664 (22.62)
10–12	511 (38.39)	1,134 (38.62)
≥ 13	170 (12.77)	440 (14.99)
Follow-up time, days^b
Mean ± SD	278.7 ± 224.7	292.3 ± 263.3
Median	210	207

Abbreviation: GEM Gemcitabine, GEM-E Gemcitabine + Erlotinib
^aDifferences between GEM and GME-E were tested with t-test for continues variable and with the chi-square test for categorical variables
^bFollow-up termination: follow-up for 3 years or until December 31, 2013 or date of death

ISSN: 1471-2407